Your browser doesn't support javascript.
Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
Subbarao, Sathyavani; Warrener, Lenesha A; Hoschler, Katja; Perry, Keith R; Shute, Justin; Whitaker, Heather; O'Brien, Michelle; Baawuah, Frances; Moss, Paul; Parry, Helen; Ladhani, Shamez N; Ramsay, Mary E; Brown, Kevin E; Amirthalingam, Gayatri.
  • Subbarao S; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Warrener LA; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Hoschler K; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Perry KR; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Shute J; Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.
  • Whitaker H; Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom.
  • O'Brien M; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Baawuah F; Brondesbury Medical Centre, Kilburn, London, United Kingdom.
  • Moss P; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Parry H; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Ladhani SN; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.
  • Ramsay ME; Paediatric Infectious Diseases Research Group, St. George's University of London, London, United Kingdom.
  • Brown KE; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
  • Amirthalingam G; Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.
Euro Surveill ; 26(12)2021 03.
Article in English | MEDLINE | ID: covidwho-1154193
Semantic information from SemMedBD (by NLM)
1. Assay USES Antibodies
Subject
Assay
Predicate
USES
Object
Antibodies
2. Vaccines TREATS Persons
Subject
Vaccines
Predicate
TREATS
Object
Persons
3. Assay USES Antibodies
Subject
Assay
Predicate
USES
Object
Antibodies
4. Vaccines TREATS Persons
Subject
Vaccines
Predicate
TREATS
Object
Persons
ABSTRACT
Sera were collected from 185 adults aged ≥ 70 years in London to evaluate the immune response to COVID-19 vaccines. A single dose of Pfizer/BioNtech vaccine resulted in > 94% seropositivity after 3 weeks in naïve individuals using the Roche Spike antibody assay, while two doses produced very high spike antibody levels, significantly higher than convalescent sera from mild-to-moderate PCR-confirmed adult cases. Our findings support the United Kingdom's approach of prioritising the first dose and delaying the second dose of COVID-19 vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Language: English Year: 2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Subject: COVID-19 Vaccines / COVID-19 / Antibodies, Viral / Antibody Formation Language: English Year: 2021
...